Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
What Is Acceptable Risk In Crypto Investing outlines how to set sensible risk boundaries to protect capital while pursuing upside in crypto markets.
26,546 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
The US dollar still dominates oil trades, but signals of strain are rising. Tensions in the Middle East and a push to...
Granite Ridge delivered a solid start to 2026 with steady revenue growth and improving margins. This article breaks d...
A provocative nickname sparked online chatter and real-world worries about policy and prices. This guide explains how...
A new Pew poll shows Democrats and Republicans share a growing worry about the federal debt, a rare bipartisan moment...
A small lithium technology firm surged to a $1B valuation after unveiling a breakthrough recovery method, signaling a...
Intel faces a pivotal moment as Q1 losses mount and cash burn deepens. Analysts and investors debate buy, hold sell i...
Nebius Group flags a fragile link between borrowing costs and AI investment. The remarks underscore how rate moves fr...
A major energy infrastructure company is funding AI data-center expansion with a generous dividend, while C3.AI conte...
A renewed bond market selloff is sharpening focus on fiscal risks. Analysts say the u.s. debt ‘elephant room’ could q...
Target just gave investors a fresh reason to rethink risk and opportunity in retail. After a solid earnings beat and ...
A coalition of fair housing and economic justice groups filed a federal lawsuit in Washington, D.C., challenging a Re...